Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine

Sharon Frey; Ron Dagan; Yaffa Ashur; Xiao Q. Chen; Jose Ibarra; Herwig Kollaritsch; Mark H. Mazur; Gregory A. Poland; Keith Reisinger; Emmanuel Walter; Pierre Van Damme; Jean H. Braconier; Ingrid Uhnoo; Martin Wahl; Mark M. Blatter; Dennis Clements; David Greenberg; Robert M. Jacobson; S. Ragnar Norrby; Mina Rowe; Daniel Shouval; Sue S. Simmons; Jan Van Hattum; Solveig Wennerholm; Jacqueline O'Brien Gress; Ivan Chan; Barbara Kuter

doi:10.1086/315119

Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine

Sharon Frey, Ron Dagan, Yaffa Ashur, Xiao Q. Chen, Jose Ibarra, Herwig Kollaritsch, Mark H. Mazur, Gregory A. Poland, Keith Reisinger, Emmanuel Walter, Pierre Van Damme, Jean H. Braconier, Ingrid Uhnoo, Martin Wahl, Mark M. Blatter, Dennis Clements, David Greenberg, Robert M. Jacobson, S. Ragnar Norrby, Mina RoweDaniel Shouval, Sue S. Simmons, Jan Van Hattum, Solveig Wennerholm, Jacqueline O'Brien Gress, Ivan Chan, Barbara Kuter

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

A randomized trial comparing 3 manufacturing consistency lots of a combination hepatitis A/hepatitis B vaccine to each other and to hepatitis A vaccine and hepatitis B vaccine given separately and concurrently was done to evaluate safety, tolerability, and immunogenicity. Healthy volunteers > 1/4 1 years of age were divided into 4 groups. Each of 3 groups received a separate consistency lot of the combination vaccine, and 1 group received separate but concurrent injections of hepatitis A and hepatitis B vaccines. Injections were given at weeks 0 and 24. The combination vaccine was generally well tolerated. The hepatitis A portion of the combination vaccine produced clinically acceptable high seropositivity rates 4 and 52 weeks after the first injection. The hepatitis B portion of the vaccine did not produce clinically acceptable seropositivity rates 4 weeks after the second injection. Lack of antibody production may be attributed, at least in part, to immunologic interference.

Original language	English (US)
Pages (from-to)	2018-2022
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	180
Issue number	6
DOIs	https://doi.org/10.1086/315119
State	Published - 1999

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Access to Document

10.1086/315119

Cite this

Frey, S., Dagan, R., Ashur, Y., Chen, X. Q., Ibarra, J., Kollaritsch, H., Mazur, M. H., Poland, G. A., Reisinger, K., Walter, E., Van Damme, P., Braconier, J. H., Uhnoo, I., Wahl, M., Blatter, M. M., Clements, D., Greenberg, D., Jacobson, R. M., Ragnar Norrby, S., ... Kuter, B. (1999). Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. Journal of Infectious Diseases, 180(6), 2018-2022. https://doi.org/10.1086/315119

Frey, S, Dagan, R, Ashur, Y, Chen, XQ, Ibarra, J, Kollaritsch, H, Mazur, MH, Poland, GA, Reisinger, K, Walter, E, Van Damme, P, Braconier, JH, Uhnoo, I, Wahl, M, Blatter, MM, Clements, D, Greenberg, D, Jacobson, RM, Ragnar Norrby, S, Rowe, M, Shouval, D, Simmons, SS, Van Hattum, J, Wennerholm, S, O'Brien Gress, J, Chan, I & Kuter, B 1999, 'Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine', Journal of Infectious Diseases, vol. 180, no. 6, pp. 2018-2022. https://doi.org/10.1086/315119

@article{a0b0af5c6a1b48778c312b2e6508f1e9,

title = "Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine",

abstract = "A randomized trial comparing 3 manufacturing consistency lots of a combination hepatitis A/hepatitis B vaccine to each other and to hepatitis A vaccine and hepatitis B vaccine given separately and concurrently was done to evaluate safety, tolerability, and immunogenicity. Healthy volunteers > 1/4 1 years of age were divided into 4 groups. Each of 3 groups received a separate consistency lot of the combination vaccine, and 1 group received separate but concurrent injections of hepatitis A and hepatitis B vaccines. Injections were given at weeks 0 and 24. The combination vaccine was generally well tolerated. The hepatitis A portion of the combination vaccine produced clinically acceptable high seropositivity rates 4 and 52 weeks after the first injection. The hepatitis B portion of the vaccine did not produce clinically acceptable seropositivity rates 4 weeks after the second injection. Lack of antibody production may be attributed, at least in part, to immunologic interference.",

author = "Sharon Frey and Ron Dagan and Yaffa Ashur and Chen, {Xiao Q.} and Jose Ibarra and Herwig Kollaritsch and Mazur, {Mark H.} and Poland, {Gregory A.} and Keith Reisinger and Emmanuel Walter and {Van Damme}, Pierre and Braconier, {Jean H.} and Ingrid Uhnoo and Martin Wahl and Blatter, {Mark M.} and Dennis Clements and David Greenberg and Jacobson, {Robert M.} and {Ragnar Norrby}, S. and Mina Rowe and Daniel Shouval and Simmons, {Sue S.} and {Van Hattum}, Jan and Solveig Wennerholm and {O'Brien Gress}, Jacqueline and Ivan Chan and Barbara Kuter",

year = "1999",

doi = "10.1086/315119",

language = "English (US)",

volume = "180",

pages = "2018--2022",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine

AU - Frey, Sharon

AU - Dagan, Ron

AU - Ashur, Yaffa

AU - Chen, Xiao Q.

AU - Ibarra, Jose

AU - Kollaritsch, Herwig

AU - Mazur, Mark H.

AU - Poland, Gregory A.

AU - Reisinger, Keith

AU - Walter, Emmanuel

AU - Van Damme, Pierre

AU - Braconier, Jean H.

AU - Uhnoo, Ingrid

AU - Wahl, Martin

AU - Blatter, Mark M.

AU - Clements, Dennis

AU - Greenberg, David

AU - Jacobson, Robert M.

AU - Ragnar Norrby, S.

AU - Rowe, Mina

AU - Shouval, Daniel

AU - Simmons, Sue S.

AU - Van Hattum, Jan

AU - Wennerholm, Solveig

AU - O'Brien Gress, Jacqueline

AU - Chan, Ivan

AU - Kuter, Barbara

PY - 1999

Y1 - 1999

N2 - A randomized trial comparing 3 manufacturing consistency lots of a combination hepatitis A/hepatitis B vaccine to each other and to hepatitis A vaccine and hepatitis B vaccine given separately and concurrently was done to evaluate safety, tolerability, and immunogenicity. Healthy volunteers > 1/4 1 years of age were divided into 4 groups. Each of 3 groups received a separate consistency lot of the combination vaccine, and 1 group received separate but concurrent injections of hepatitis A and hepatitis B vaccines. Injections were given at weeks 0 and 24. The combination vaccine was generally well tolerated. The hepatitis A portion of the combination vaccine produced clinically acceptable high seropositivity rates 4 and 52 weeks after the first injection. The hepatitis B portion of the vaccine did not produce clinically acceptable seropositivity rates 4 weeks after the second injection. Lack of antibody production may be attributed, at least in part, to immunologic interference.

AB - A randomized trial comparing 3 manufacturing consistency lots of a combination hepatitis A/hepatitis B vaccine to each other and to hepatitis A vaccine and hepatitis B vaccine given separately and concurrently was done to evaluate safety, tolerability, and immunogenicity. Healthy volunteers > 1/4 1 years of age were divided into 4 groups. Each of 3 groups received a separate consistency lot of the combination vaccine, and 1 group received separate but concurrent injections of hepatitis A and hepatitis B vaccines. Injections were given at weeks 0 and 24. The combination vaccine was generally well tolerated. The hepatitis A portion of the combination vaccine produced clinically acceptable high seropositivity rates 4 and 52 weeks after the first injection. The hepatitis B portion of the vaccine did not produce clinically acceptable seropositivity rates 4 weeks after the second injection. Lack of antibody production may be attributed, at least in part, to immunologic interference.

UR - http://www.scopus.com/inward/record.url?scp=0032731101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032731101&partnerID=8YFLogxK

U2 - 10.1086/315119

DO - 10.1086/315119

M3 - Article

C2 - 10558961

AN - SCOPUS:0032731101

SN - 0022-1899

VL - 180

SP - 2018

EP - 2022

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 6

ER -

Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this